Результаты поиска

Ciltacabtagene Autoleucel for the Treatment of Relapsed/Refractory Multiple Myeloma: Efficacy, Safety, and Place in Therapy.

Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) are two chimeric antigen receptor T cell (CAR T) therapies approved for use in patients with relapsed/refractory multiple myeloma (MM). Initially approved for late line MM (>4 prior lines), these were recently approved for use in MM with 1-2 prior lines of therapy in April 2024. As their use outside of the pivotal clinical trials continues to expand, it is important to critically evaluate the safety and efficacy of these therapies. Further, it is important to identify patients that would be most likely to benefit from t

Inflammation and Cancer: Molecular Mechanisms and Therapeutic Targets.

Inflammation is a core pathological factor regulating tumor initiation, progression, and therapeutic resistance, and elucidating its molecular crosstalk with tumors is crucial for developing effective clinical therapies. Internal drivers of inflammation-tumor transformation include genomic disorder, epigenetic memory, mitochondrial stress, and metabolic reprogramming, which synergistically initiate carcinogenesis. External factors amplifying tumor progression cover immune dysfunction, stromal fibrosis, microbial dysbiosis, vascular neoplasia, and neurotoxicity, collectively accelerating tumor

Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, December 5th 2015

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Efficacy of Technology-Based Cognitive Rehabilitation Tools for Cancer-Related Cognitive Impairment in Non-CNS Cancer Patients: A Systematic Review.

Background: Cancer-related cognitive impairment (CRCI) is a significant concern for individuals with non-central nervous system (non-CNS) cancers, affecting memory, attention, executive functions, and processing speed. Non-pharmacological interventions, including digital cognitive rehabilitation, have shown promise in addressing CRCI. This systematic review investigates the efficacy of digital and computerized cognitive rehabilitation interventions in improving cognitive outcomes in non-CNS cancer patients. Method: A systematic search of the EMBASE, Scopus, and PubMed databases was conducted t

Совпадение в полном тексте источника
… For instance, episodic memory in breast cancer survivors often exhibits delayed or partial recovery, likely due to neurotoxic effects of chemotherapy on the hippocampus, a key brain area for episodic memory consolidation [ 33 ]. …

Optimization of older adults by a geriatric assessment-guided multidisciplinary clinic before CAR T-cell therapy.

AbstractThe optimal means of assessing candidacy of older adults (≥65 years) for chimeric antigen receptor T-cell (CAR-T) therapy are unknown. We explored the role of a geriatric assessment (GA)-guided multidisciplinary clinic (GA-MDC) in selecting and optimizing older adults for CAR-T. Sixty-one patients were evaluated in a GA-MDC (median age, 73 years; range, 58-83). A nonbinding recommendation ("proceed" or "decline") regarding suitability for CAR-T was provided for each patient based on GA results. Fifty-three patients ultimately received CAR-T (proceed, n = 47; decline, n = 6). Among pati

Abstracts From JADPRO Live at APSHO 2015.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma.

Despite the improvement in survival outcomes, multiple myeloma (MM) remains an incurable disease. Chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA) represents a new strategy for the treatment of relapsed/refractory MM (R/R). In this paper, we describe several recent advances in the field of anti-BCMA CAR T-cell therapy and MM. Currently, available data on anti-BCMA CART-cell therapy has demonstrated efficacy and manageable toxicity in heavily pretreated R/R MM patients. Despite this, the main issues remain to be addressed. First of all, a significant pro

Окисляющий стресс в функции мозга.

Окисляющий стресс (OS) является важным фактором в патофизиологии многочисленных нейродегенеративных расстройств, таких, как болезнь Паркинсона, множественный склероз, цереброваскулярная патология или болезнь Альцгеймера. OS также оказывает значительное влияние на прогресс между различными нейродегенеративными расстройствами. Несбалансированность между образованием реактивных видов кислорода (РОС) и способностью организма нейтрализовать эти токсичные побочные продукты делает мозг подверженным окислительным повреждениям. Увеличение количества ROS может привести к сбоям в клетке, апоптозу и нейро

Совпадение в полном тексте источника
… Choline, phosphatidylserine, citicoline and choline alphoscerates contribute to memory consolidation. Choline is a crucial component in the formation of phospholipids and serves as a precursor for acetylcholine. …

The 44th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Poster Sessions

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Стриато-лимбическая и лобная дисфункция, лежащая в основе дисбаланса в мотивации вознаграждения и когнитивном контроле в навязанном сексуальном поведении: нейроимационный метаанализ.

СТРУКТУРА: Навязчивое сексуальное расстройство (CSBD) связано с неконтролируемыми сексуальными желаниями и поведением, вызывающими расстройство или функциональные расстройства. Несмотря на то, что он классифицируется как расстройство контроля импульсов в МКБ-11, его нейробиологическая основа и когнитивные недостатки по-прежнему плохо понимаются. Достижения в крупных языковых моделях (МЛМ) позволяют производить масштабируемую обработку литературы и синтез мультимодальных нейроимаций. В этом исследовании использовались основанные на LLM рамки для метаанализа на основе координат и функционального

A review of immunotherapy for bone tumors.

This article reviews the latest research progress in immunotherapy for bone tumors. Bone tumors are a serious threat to human health, and traditional treatments have limitations. Recently, immunotherapy, as an emerging treatment method, has shown great potential in the treatment of bone tumors. This article systematically introduces the pathological features, traditional treatment methods and limitations of bone tumors, and focuses on the principles, application status and challenges of immune checkpoint inhibitors, CAR-T cell therapy, tumor vaccines and other immunotherapies. At the same time

Breaking Boundaries: Immunotherapy for Myeloid Malignancies.

Immunotherapy has revolutionized the treatment of myeloid oncologic diseases, particularly for patients resistant to chemotherapy or ineligible for allogeneic stem cell transplantation due to age or fitness constraints. As our understanding of the immunopathogenesis of myeloid malignancies expands, so too do the treatment options available to patients. Immunotherapy in myeloid malignancies, however, faces numerous challenges due to the dynamic nature of the disease, immune dysregulation, and the development of immune evasion mechanisms. This review outlines the progress made in the field of im

Bispecific antibodies in the treatment of multiple myeloma.

The treatment paradigm in myeloma is constantly changing. Upfront use of monoclonal antibodies like daratumumab along with proteasome inhibitors (PI)s, and immune modulators (IMiD)s have significantly improved survival and outcomes, but also cause unique challenges at the time of relapse. Engaging immune T cells for tumour cell kill with chimeric antigenic T-cell (CAR T-cell) therapy and bispecific antibodies have become important therapeutic options in relapsed multiple myeloma. Bispecific antibodies are dual antigen targeting constructs that engage the T cells to plasma cells through various

2019 ASCO Annual Meeting Highlights for the Advanced Practitioner: Hematologic Malignancies.

Amy Pierre, MSN, ANP-BC, of the Memorial Sloan Kettering Cancer Center, and Nancy M. Nix, PharmD, BCPS, BCOP of St. Joseph's/Candler Health System offer an advanced practitioner perspective on trials assessing the efficacy and safety of novel agents in smoldering and relapsed/refractory multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia.

Defining neuroblastoma: From origin to precision medicine.

Neuroblastoma (NB), a heterogenous pediatric tumor of the sympathetic nervous system, is the most common and deadly extracranial solid malignancy diagnosed in infants. Numerous efforts have been invested in understanding its origin and in development of novel curative targeted therapies. Here, we summarize the recent advances in the identification of the cell of origin and the genetic alterations occurring during development that contribute to NB. We discuss current treatment regimens, present and future directions for the identification of novel therapeutic metabolic targets, differentiation

Implementation of electronic prospective surveillance models in cancer care: a scoping review.

BackgroundElectronic prospective surveillance models (ePSMs) for cancer rehabilitation include routine monitoring of the development of treatment toxicities and impairments via electronic patient-reported outcomes. Implementing ePSMs to address the knowledge-to-practice gap between the high incidence of impairments and low uptake of rehabilitation services is a top priority in cancer care.MethodsWe conducted a scoping review to understand the state of the evidence concerning the implementation of ePSMs in oncology. Seven electronic databases were searched from inception to February 2021. All a

Интеграция арт-терапии и технологии в нейрореабилитацию: обзор аналитического исследования.

Лечение фона Арта становится многообещающим дополнением к нейрореабилитации, обеспечивая творческое участие в улучшении моторных, когнитивных и эмоциональных результатов. Цифровые технологии, такие, как виртуальная реальность (ВПР), усиленная реальность (АР), экзогамы и сенсорные системы, позволяют получить погруженный и интерактивный терапевтический опыт, потенциально повышающий эффективность реабилитации. В рамках этого аналитического обзора проводится систематическая оценка воздействия арт-терапии с использованием технических средств на неврологическую реабилитацию и выявляются эффективные

Multiple Myeloma in 2023 Ways: From Trials to Real Life.

Multiple myeloma is a chronic hematologic malignancy that obstinately tends to relapse. Basic research has made giant strides in better characterizing the molecular mechanisms of the disease. The results have led to the manufacturing of new, revolutionary drugs which have been widely tested in clinical trials. These drugs have been approved and are now part of the therapeutic armamentarium. As a consequence, it is essential to combine what we know from clinical trials with real-world data in order to improve therapeutic strategies. Starting with this premise, our review aims to describe the cu

Текущее качество жизненных вопросников не имеет значения для оценки проблем QOL у многих пациентов миэломы в эпоху современной терапии: результаты обследования, проведенного с пациентами миэломы и специалистами в области здравоохранения миеломы.

Поскольку многие пациенты миеломы (ММ) живут дольше, поддержание качества жизни (КОЛ) стало важной целью лечения. В то же время широко используемые вопросники по общему качеству жизни (QOLQs) были разработаны по сравнению с 20 Много лет назад. В этом обследовании 224 Пациенты ММ и 48 К специалистам в области здравоохранения (ХЦП) была обращена просьба оценить актуальность и важность предметов КОЛ из 9 аттестованные, часто используемые MM QOLQs. Результаты этого обследования выявили значительные расхождения в восприятии пациентами из числа ММ и ХЦП важных и актуальных вопросов КОЛ. Несмотря на

Mortality Audit of Cancer Patients in the Department of Medical Oncology at a Tertiary Cancer Care Centre in South India.

Considerable advances in the diagnosis and treatment of cancer have made a huge impact on morbidity and mortality from neoplastic diseases. However, cancer remains the leading cause of death across the world. This is a retrospective study carried out at a tertiary cancer care centre (Kidwai Memorial Institute of Oncology, Bangalore) in South India. Case records of all cancer patients who died while receiving inpatient treatment between January 2022 and December 2022 under the Department of Medical Oncology were reviewed and studied. There was a total of 240 deaths. Out of these, the majority o